NEUROENDOCRINE NEOPLASM

This study tests whether two drugs, lenvatinib and everolimus, can shrink or slow the growth of advanced carcinoid tumors that cannot be removed by surgery. The drugs work by blocking enzymes that help cancer cells grow. The trial includes 36 adults with confirmed carcinoid tumor…

This study tests whether adding an immunotherapy drug (pembrolizumab) to either liver-directed treatments or a targeted radiation therapy (PRRT) can shrink tumors in people with neuroendocrine tumors that have spread to the liver. About 32 adults with well-differentiated tumors t…

This phase 3 study tests the drug cabozantinib against a placebo in 298 people with advanced neuroendocrine tumors (including carcinoid tumors) that have worsened after prior treatment. Cabozantinib is a targeted therapy that may slow or stop tumor growth by blocking certain prot…

This early-phase trial tests a new drug (peposertib) combined with a radioactive treatment (lutetium Lu 177 dotatate) for people with a type of neuroendocrine tumor. The goal is to find the safest and most effective dose, and to see if the combination can shrink tumors or slow th…

This study compares two drug combinations for people with advanced neuroendocrine tumors (a type of slow-growing cancer). 427 participants received either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better delays cancer growth. …

This early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, helping PET scans show where cancer is located. Researchers want to see how well the tracer works and compare it to standard imaging. T…